| Budget Amount *help |
¥17,420,000 (Direct Cost: ¥13,400,000、Indirect Cost: ¥4,020,000)
Fiscal Year 2017: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2015: ¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
|
|---|
| Outline of Final Research Achievements |
We have developed the new glyco-compound to inhibit biosynthesis of cancer-related fucosylation. This compound suppressed invasiveness in the liver cancer cell lines. We also revealed molecular structure of GnT-V which is the glycosyltransferase to enhance cancer metastasis. This proved the unique character for GnT-V. For Alzheimer’s disease, we have identified GnT-III as the glycosyltransferase related to disease state, and performed screening study to discover compounds to inhibit GnT-III. In COPD study, we have produced more effective keratan sulfate disaccharide L4 polymer by chemosynthesis. This L4 polymer suppressed inflammatory response of immune cells by the stronger binding to C-type lectins.
|
